Antitumor Activity of Bortezomib (PS-341; Velcade) in a Phase II Study of Patients with Previously Untreated or Treated Waldenstrom’s Macroglobulinemia (WM).
Notice bibliographique
Résumé
Abstract Background: WM is a clonal disorder of lymphoplasmacytoid cells that shares features with lymphoma and myeloma. It is generally considered an indolent lymphoma hence traditional first-line treatments include single-agent alkylators (RR 50–80%) or purine analogues (RR 70–80%). For relapsed/refractory disease, purine analogues lead to responses in only 30% of pts. Newer agents such as rituximab or thalidomide have moderate activity. Regardless of regimen, responses tend to be partial and transient. Bortezomib is a proteasome inhibitor that has shown activity in myeloma. Objective responses were reported in phase I studies of lymphoma, including WM, making this agent of interest to evaluate. Methods: Eligible pts for this ongoing multicentre study must have symptomatic WM (Hb <110g/L; symptomatic lymphadenopathy; hepatomegaly and/or splenomegaly; or hyperviscosity) and received <3 prior chemotherapy regimens (rituximab allowed as a 3rd regimen). Pts receive bortezomib 1.3 mg/m2 IV bolus twice weekly x 2 wks on a 3 wk cycle until PD or 2 cycles beyond CR/stable PR. Planned accrual = 25 pts. Results: Sixteen pts are enrolled thus far. Demographics: median age 63 (range 46–87), M:F ratio = 9:7, ECOG 0:1:2 ratio = 5:10:1. Eight of 16 pts were chemonaive; 8 previously treated (prior regimens: chlorambucil, cladribine, fludarabine, CHOP). At study entry, most pts (12/16) had IgM levels >30g/L (range 11.2–79.8), measurable nodal disease (10/16 pts), and Hb levels <110g/L (10/16 pts). Responses have been observed: 3 confirmed PR (≥50% decrease in both IgM and bidimensional disease), 10 SD, no CR (of 13 evaluable pts). PR in 3 pts was reached after 3, 4, and 8 cycles, respectively. No pts have progressed on treatment. A ≥50% decrease in IgM alone with lagging nodal responses has been observed in another 3 pts. Therefore, a total of 6/13 pts (46%) have achieved PR based on paraprotein response alone. Hematologic improvements (Hb increases ≥ 10g/L) were observed in 9/13 pts (69%). Most common toxicities: fatigue (69%), sensory neuropathy (61.5%), headache (54%), myalgias (61.5%). Neuropathy is described as tingling, numbness, or pain in feet/legs generally within 2–4 cycles. Gr 3 neuropathy developed in 4 pts (none had clinical neuropathy at baseline). Four pts were removed from study due to neuropathy. Reversibility of neuropathy is pending longer followup. Other Gr 3 toxicities: thrombocytopenia (3/13), myalgias (2/13), neutropenia (2/13). Thrombocytopenia and neutropenia were transient, mandating a dose reduction in only 1 pt (neutropenia). Gr 3 myalgias (leg cramps) led to drug discontinuation in 1 pt with rapid resolution. No Gr 4 toxicities have been reported. Conclusions: Bortezomib appears to have activity in WM with objective responses in 3 of 13 pts and SD in 10 additional pts evaluable thus far. Despite prompt IgM reductions and hematologic improvements, objective responses are slow due to lags in nodal reductions. Bortezomib is well-tolerated although sensory neuropathy is common. These interim results are promising and encourage further study of this drug in WM.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,000 |
| Bibliométrie | 0,000 | 0,001 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».